Navigation Links
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Date:9/4/2008

Updated Survival Data for Ipilimumab to be Presented

PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm. Many of the following abstracts will include updated one-year survival data from three Phase 2 studies (008, 022 and 007) in previously treated patients with advanced metastatic melanoma:

Ipilimumab Presentations in Advanced Melanoma

-- "Efficacy and safety of patients with advanced melanoma treated with ipilimumab with or without the addition of prophylactic budesonide" (Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy" (Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab-mediated patterns of response in patients with pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases" (Abstract #786P) J. S. Weber - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster presentation and discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma - results from a Phase 2, randomized, dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of treatment-naive and previously treated patients with advanced melanoma receiving ipilimumab" (Abstract #778PD) R. Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Prolonged stable disease in ipilimumab-treated patients with advanced melanoma who have progressed on prior anticancer therapies" (Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

More information about the ESMO Congress may be found at http://www.esmo.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Denmark , March 23, 2017 Ascendis ... its innovative TransCon technology to address significant unmet medical ... will host a conference call and webcast on Monday, ... the Endocrine Society in Orlando, Florida ... disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and ...
(Date:3/23/2017)... 2017  Cornerstone Pharmaceuticals, Inc., a clinical-stage, ... today.  Following successful End-of-Phase I (EOP1) Type ... Drug Administration (FDA), the Company has been ... forward to conduct pivotal trials of its ... myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... AVIV, Israel , March 23, 2017 ... on oncology and immunology, announced today that it has acquired ... immunotherapy platform. Acquisition consideration consisted of a $6 million upfront ... remainder in BioLineRx shares. Additional future payments may be made ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... program owned and organized by HMP Communications Holdings, LLC, today announced that ... within its nationwide network of wound centers interested in becoming Certified Wound Specialist ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... solutions, today named The Resource Group as their 2016 Microsoft Dynamics Partner of ... in Newport Beach, CA. The award recognizes The Resource Group for their ...
(Date:3/23/2017)... Boca Raton, FL (PRWEB) , ... March 23, ... ... range of dietary supplements that help improve all aspects of people’s health and ... popular website for nutritional products. , Natural Subsistence develops nutritional supplements that ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with all Americans facing life-altering and fatal diseases in opposition to the ... decisions that would eviscerate care, services, and hope for the most vulnerable among ...
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
Breaking Medicine News(10 mins):